Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness of 188Re-SSS Lipiodol Therapy for Patients with Non-Operable Liver Cancer

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of liver cancer called hepatocellular carcinoma, which cannot be removed through surgery. The treatment being tested is called 188Re-SSS Lipiodol, a solution that is injected directly into the liver's blood vessels. This treatment is a form of internal radiation therapy, which means it uses radiation to target and kill cancer cells from within the body.

The purpose of the study is to evaluate how effective this treatment is for patients with non-operable hepatocellular carcinoma. Participants in the study will receive the 188Re-SSS Lipiodol injection and will be monitored over time to see how their cancer responds to the treatment. The study will look at various outcomes, such as how well the cancer shrinks, how long it takes for the cancer to progress, and the overall survival of the patients. These outcomes will be assessed at different intervals, including one month, three months, and every three months up to two years after the treatment.

Throughout the study, researchers will also measure levels of a protein called alpha-fetoprotein (AFP) in the blood, which can indicate how the cancer is responding to the treatment. A decrease in AFP levels may suggest a positive response to the therapy. The study aims to provide valuable information on the potential benefits of 188Re-SSS Lipiodol for patients with this type of liver cancer.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to provide your consent by signing an informed consent form. This confirms your understanding of the study and your willingness to participate.

    You must meet certain criteria to participate, including being 18 years or older, having a specific type of liver cancer that cannot be operated on, and having a good general health status as determined by a performance scale.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm your eligibility. This includes verifying your medical history and conducting necessary tests to ensure you meet all the study requirements.

    Your liver condition will be evaluated, and the extent of tumor involvement will be assessed to ensure it is less than 50% of the liver.

  3. Step 3

    Treatment administration

    You will receive the treatment called 188Re-SSS Lipiodol, which is a solution for injection. This will be administered directly into the artery that supplies blood to the liver, a method known as intraarterial use.

    The treatment aims to deliver targeted radiation therapy to the liver tumor.

  4. Step 4

    Follow-up assessments

    After the treatment, follow-up assessments will be conducted at 1 month, 3 months, and every 3 months up to 24 months. These assessments will evaluate the response of the tumor to the treatment.

    The primary focus will be on measuring the tumor's response, progression of the disease, and overall survival.

  5. Step 5

    Monitoring and evaluation

    Throughout the study, your health and response to the treatment will be closely monitored. This includes regular blood tests to measure levels of a protein called alpha-fetoprotein (AFP), which can indicate how well the treatment is working.

    The study will also track the time it takes for the cancer to progress and overall survival rates.

Who can join the trial?

9 criteria

  • Must be 18 years or older.
  • Have an ECOG Performance Status of 0-1, which means you are fully active or have some symptoms but can still carry out light work.
  • Have a diagnosis of Hepatocellular Carcinoma (a type of liver cancer) confirmed by tests or according to specific medical guidelines.
  • The cancer must be non-operable and cannot be treated with a procedure called ablation therapy.
  • Have at least one tumor that can be measured using a specific method called mRECIST.
  • The tumor must involve less than 50% of the liver.
  • Be classified as stage A to C according to the BCLC classification, which is a system used to stage liver cancer.
  • If you have cirrhosis (liver scarring), it must be compensated cirrhosis, classified as Child Pugh A or B7, meaning the liver is still functioning well.
  • Must provide informed consent by signing a document that explains the study, or have a legal representative sign it for you.

Who cannot join the trial?

8 criteria

  • Patients who have had surgery to remove the liver cancer cannot participate.
  • Patients who are younger than 18 years old or older than 65 years old are not eligible.
  • Patients who are pregnant or breastfeeding cannot take part in the study.
  • Patients with other serious health conditions that might interfere with the study treatment are excluded.
  • Patients who have participated in another clinical trial within the last 30 days are not allowed to join.
  • Patients who have allergies to the study medication or its ingredients cannot participate.
  • Patients with a history of alcohol or drug abuse may be excluded.
  • Patients who are unable to follow the study procedures or attend the required visits are not eligible.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

188Re-SSS lipiodol is a special type of treatment used for liver cancer that cannot be removed with surgery. This therapy involves injecting a radioactive substance directly into the liver. The goal is to target and destroy cancer cells while minimizing damage to healthy tissue. The radioactive material helps to shrink the tumor and slow down its growth, providing a treatment option for patients who have limited choices due to the inoperable nature of their cancer.

What is already known about the treatment

188Re-SSS lipiodol – This medication is administered through a method called Selective Internal Radiation Therapy, where it is directly delivered to the liver to treat non-operable liver cancer, specifically hepatocellular carcinoma. Currently, it is being studied in clinical trials to assess its effectiveness, and it is not yet widely available in standard medical practice. The main therapeutic use of 188Re-SSS lipiodol is to target and treat liver cancer that cannot be removed by surgery. At the molecular level, it works by delivering radiation directly to the cancer cells, which helps to destroy them while minimizing damage to surrounding healthy tissue. This medication falls under the pharmacological classification of radiopharmaceuticals, which are drugs that contain radioactive substances used to treat or diagnose diseases.

Investigated diseases

Hepatocellular carcinoma – Hepatocellular carcinoma is a type of liver cancer that originates in the hepatocytes, the main type of liver cell. It typically develops in the context of chronic liver disease, often related to hepatitis or cirrhosis. The disease progresses as the cancerous cells multiply and form a tumor, which can disrupt liver function. As the tumor grows, it may invade nearby blood vessels and spread to other parts of the liver or beyond. Symptoms may include abdominal pain, weight loss, and jaundice, although they often appear in advanced stages. The progression of the disease can lead to further complications, such as liver failure or metastasis to other organs.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-503341-60-00Protocol code2017-1-14-010Estimated enrolment35 patientsSponsorCentre De Lutte Contre Le Cancer Eugene Marquis

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.